2seventy bio에 대한 매도 수량은 투자자에게 2seventy bio의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

2seventy bio (NASDAQ:TSVT) 주식, 공매도 수량 보고

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

2seventy bio Inc

WIIM

AMAT

AMBA

KLAC

LRCX

MRVL

MTSI

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

UCTT

Shares of chip stocks are trading higher as tech stocks rebound following softer-than-expected Feb. CPI figures. It was also reported that TSMC pitched a joint venture to Nvidia, AMD, Broadcom and Qualcomm to operate Intel's factories.

On Wednesday, Gilead Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) presented data from its HIV treatment portfolio and pipeline at the&nbsp;Conference on Retroviruses and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Opportunistic Infections&nbsp;(CROI 2025)</a>.
ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44273943/gilead-presents-new-hiv-treatment-and-cure-research-data-at-croi-2025-including-an-investigational" rel="noreferrer noopener">coinfection initiating treatment</a>.
<ul>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanhiv%2Farticle%2FPIIS2352-3018%252823%252900151-0%2Ffulltext&amp;esheet=54222729&amp;newsitemid=20250311386143&amp;lan=en-US&amp;anchor=Previously+reported+results&amp;index=3&amp;md5=10debf8f20cc3e5d6237cdbbcf58ee3a" target="_blank" rel="noreferrer noopener">Previously reported results</a> demonstrated the efficacy of both antiretroviral regimens.</li>
<li>The newly presented data shows that Biktarvy maintained high rates of HIV-1 (95.4%) and HBV (86.6%) virologic suppression, defined as HIV RNA &lt;50 copies/ mL and HBV DNA &lt;29 IU/ mL, respectively, in participants (n=89) following a switch to Biktarvy after 96 weeks of treatment with DTG+ F/TDF.</li>
<li>Study drug-related treatment-emergent adverse events were reported in 19% of participants and most were mild to moderate, with zero discontinuations due to TEAEs.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention" rel="noreferrer noopener">Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention</a>
At CROI 2025, the primary results of a Phase 2 study evaluating lenacapavir (LEN) with teropavimab (TAB) and zinlirvimab (ZAB) (LTZ) were presented.
<ul>
<li>The study met its primary endpoint: the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26.</li>
<li>The Week 26 data demonstrated the high efficacy of the LTZ regimen, with 96% of participants who received LTZ and 96% (n=26 of 27) who received SBR, remained virologically suppressed.</li>
<li>CD4 cell counts also increased from baseline to week 26 in both groups.</li>
<li>The most common AEs with LTZ were injection site reactions related to subcutaneous LEN administration.</li>
</ul>
The Phase 2a GS-US-382-5445 trial enrolled 20 South African cisgender women who had received antiretroviral therapy (ART) soon after acquiring HIV and were virologically suppressed for at least 12 months.
<ul>
<li>Participants received up to 10 oral doses of Gilead&#8217;s vesatolimod, every 2 weeks starting on day 0, plus IV infusions of broadly neutralizing antibodies (bNAbs) VRC07-523LS and CAP256V2LS, provided by the National Institutes of Health.</li>
<li>Results presented at CROI showed the treatment combination was generally well-tolerated with no treatment-related serious adverse events (TEAEs) reported.</li>
</ul>
Price Action: GILD stock is up 0.04% at $114.47 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44277627/ge-aerospace-doubles-down-on-us-manufacturing-with-1b-investment-details" target="_blank" rel="noreferrer noopener">GE Aerospace Doubles Down On US Manufacturing With $1B Investment: Details</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

News

Health Care

General

GILD

Gilead Presents New HIV Treatment And Cure Research Data

Macro Economic Events

Econ #s

Economics

Trump: NATO Can Be A Force For The Good

AVGO

NVDA

QCOM

Shares of NVIDIA, Broadcom, Qualcomm and AMD are trading higher following a report suggesting TSMC pitched a joint venture to the companies to operate Intel's factories.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Dave Weiner upgraded the rating for Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Neutral to Overweight and raised the price target from $11.5 to $12.5. Myriad Genetics shares closed at $10.25 on Tuesday. <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>CL King analyst Andrew Wolf upgraded the rating for United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) from Neutral to Buy and announced a $33 price target. United Natural Foods shares closed at $24.57 on Tuesday. <a href="https://www.benzinga.com/quote/UNFI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Ryan Macwilliams upgraded HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) from Equal-Weight to Overweight and maintained the price target of $815. HubSpot shares closed at $590.67 on Tuesday. <a href="https://www.benzinga.com/quote/HUBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine upgraded the rating for Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Hold to Buy and maintained the price target of $110. Crocs shares closed at $98.32 on Tuesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) from Sector Weight to Overweight and announced a $340 price target. Eaton shares closed at $282.31 on Tuesday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HUBS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-1024x582.png" alt="" class="wp-image-821390" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86.png 1073w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>

Upgrades

Markets

Analyst Ratings

Trading Ideas

CROX

HUBS

MYGN

UNFI

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Tesla Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) trend might not be in a good space. The <a href="https://www.benzinga.com/topic/tesla" target="_blank" rel="noreferrer noopener">new U.S. registrations</a> for the Elon Musk led electric vehicle maker slipped 11% in January 2025, while rival registrations noted a 44% rise, led by Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), Chevrolet, and Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>), Automotive News <a href="https://www.autonews.com/tesla/an-tesla-us-sales-fall-as-evs-rise-overall-0312/#:~:text=U.S.%20registrations%20sink%2011%25%20in%20January%20as%20EV%20rivals%20surge%2044%25&amp;text=Tesla's%20new%20U.S.%20registrations%20fell,S%26P%20Global%20Mobility%20data%20showed." target="_blank" rel="noreferrer noopener">cited</a> S&amp;P Global Mobility data on Wednesday.
Another report last week from the <a target="_blank" href="https://www.benzinga.com/news/global/25/02/43934934/new-tesla-registrations-dip-by-50-in-eu-in-january-despite-rising-overall-bev-market-share" rel="noreferrer noopener">auto industry body</a> said 7,517 new Tesla cars were registered in the E.U. in January,&nbsp;down from 15,130 in 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/25/03/44229408/alibaba-unveils-new-ai-chip-to-power-chinas-open-source-tech-push-challenge-us-chip-giants" rel="noreferrer noopener">Alibaba Unveils New AI Chip To Power China&#8217;s Open-Source Tech Push, Challenge US Chip Giants</a>
According to the European Automobile Manufacturers Association (ACEA), Tesla&#8217;s new car registration&nbsp;in the E.U. fell by over 50%&nbsp;in January despite a rise in overall battery electric vehicle registrations.
According to the Society of Motor Manufacturers and Traders (SMMT) data, Tesla had <a target="_blank" href="https://www.benzinga.com/tech/25/02/43520687/byd-overtakes-tesla-in-uk-after-elon-musk-led-ev-makers-new-vehicle-registrations-drop-in-january" rel="noreferrer noopener">1,458 registrations in</a> January in the U.K., down from the 1,581 registered in 2024. BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), in comparison, had 1,614 registrations, up by 551%.
Tesla researcher&nbsp;Troy Teslike&nbsp;said the EV company would likely not deliver 500,000 vehicles in a quarter in 2025, citing <a target="_blank" href="https://www.benzinga.com/tech/25/02/43967968/tesla-unlikely-to-deliver-500000-evs-in-a-quarter-in-2025-says-researcher-doesnt-seem-possible-this-year-either" rel="noreferrer noopener">brand sentiment issues</a>.
On the flip side, Tesla chief Elon Musk&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44269513/elon-musk-says-tesla-will-double-us-production-in-2-years-after-trump-backs-ev-giant-amid-stock-slump" rel="noreferrer noopener">has announced that</a> Tesla&nbsp;will double vehicle production in the U.S. within two years.
Recently, President Donald Trump transformed the White House to showcase Tesla vehicles in solidarity with&nbsp;his senior advisor and de facto head of the Department of Government Efficiency (DOGE), Musk and his company. Trump also&nbsp;purchased a Tesla Model S Plaid.
Musk has acknowledged the challenges of running his business while working with DOGE amid a massive decline in Tesla&#8217;s stock price.&nbsp;
Tesla has faced protests against the company in the U.S. and Europe, with demonstrators criticizing Musk&#8217;s political activities.&nbsp;
According to <a target="_blank" href="https://www.statista.com/outlook/mmo/electric-vehicles/united-states" rel="noreferrer noopener">Statista</a>, the EV market in the U.S. could generate revenue of $104.7 billion in 2025 <a target="_blank" href="https://www.statista.com/outlook/mmo/electric-vehicles/united-states" rel="noreferrer noopener">and grow at an annual</a> rate (CAGR 2025-2029) of 10.53%, resulting in a projected market volume of $156.3 billion by 2029. Tesla&#8217;s upcoming earnings in April might be a good proxy for the recent reports on declining trends.
Price Action: TSLA stock is up 7.60% at $248.11 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44229157/apple-supplier-foxconn-unveils-ai-model-using-nvidia-tech" target="_blank" rel="noreferrer noopener">Apple Supplier Foxconn Unveils AI Model Using Nvidia Tech</a></li>
</ul>
Photo via Shutterstock

Movers

Tech

Media

BYDDY

TSLA

VWAGY

Tesla Loses Ground in US EV Market While Rivals Accelerate Ahead in January: Report

B. Riley Securities analyst Mike Crawford maintains Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Neutral and lowers the price target from $27 to $25.

Price Target

B. Riley Securities Maintains Neutral on Redwire, Lowers Price Target to $25

Ciena Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares were climbing Wednesday after the company announced <a href="https://www.benzinga.com/news/earnings/25/03/44245291/ciena-q1-earnings-revenue-and-eps-beat-estimates-ceo-eyes-ai-cloud-network-tailwinds">upbeat fiscal first-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">Needham On Ciena</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5bab9cad211e200001963493/ryan-koontz">Analyst Ryan Koontz</a> maintained a Buy rating while reducing the price target from $95 to $90.
Ciena's quarterly revenues grew 3% year-on-year to $1,072 million, beating consensus of $1,052 million, Koontz said in a note. Non-GAAP earnings of 64 cents per share were well above expectations of 41 cents per share, with gross margins coming in much higher than expected, he added.
Some investors grew concerned as management's fiscal second-quarter guidance was only in line with expectations, the analyst stated. "Strong execution paired with best-in-class technology and customer relationships should see CIEN continue to gain meaningful market share in its core TAM, although we are less bullish on its two new product segments," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Rosenblatt Securities On Ciena</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/628b6bab3547bd000104dc00/mike-genovese">Analyst Mike Genovese</a> reaffirmed a Neutral rating while cutting the price target from $79 to $73.
Ciena's healthy quarterly results were highlighted by strong orders, backlog build and gross margins, Genovese said. He added that the company's revenue guidance for the fiscal second quarter was not as strong as the beat.
Management maintained the full-year gross margin guidance at 42%-44% despite the first-quarter gross margins of 44.7%, which exceeded consensus by 270 basis points, the analyst stated.
The Street seemed to be concerned about the impact of tariffs and "demand destruction" from a potential recession this year, he further wrote.
<h1 class="wp-block-heading">Stifel On Ciena</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad935ab85e930001f97192/ruben-roy">Analyst Ruben Roy</a> reiterated a Buy rating and price target of $95.
Ciena reported strong results across the board, Roy said. The company's order momentum continued, with direct orders from cloud service providers representing over 50% of overall orders during the quarter, he added.
With SP revenues growing 14% in the first quarter, "We continue to believe that CIEN is the best way to play our expectations for a continued SP recovery over the next 12-18 months," the analyst wrote. 
Management indicated that its guidance could be missed depending on "the outcome of proposed tariffs," he further stated.
CIEN Price Action: Shares of Ciena had risen by 4.18% to $66.62 at the time of publication on Wednesday.
Read More: • <a href="https://www.benzinga.com/government/regulations/25/02/43949618/cisco-and-nvidia-expand-ai-partnership-secure-us-government-authorization-for-cloud-security">Cisco and Nvidia Expand AI Partnership, Secure US Government Authorization for Cloud Security</a>
Photo: Courtesy Ciena

Analyst Color

Earnings Beats

Guidance

Reiteration

CIEN

Ciena Posts Solid Q1 Beat, Raise; Guidance Could Be Missed Depending On 'Outcome Of Proposed Tariffs'

B. Riley Securities analyst Ryan Pfingst maintains FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) with a Neutral and lowers the price target from $12 to $9.

FCEL

B. Riley Securities Maintains Neutral on FuelCell Energy, Lowers Price Target to $9

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 4.05% on an annualized basis producing an average annual return of 12.15%. Currently, Molina Healthcare has a market capitalization of $18.03 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $999.24 today based on a price of $324.81 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741797932_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 20 Years

B. Riley Securities analyst Dave Kang maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and lowers the price target from $97 to $89.

B. Riley Securities Maintains Buy on Ciena, Lowers Price Target to $89

COTY

ULTA

Shares of beauty and cosmetics companies are trading lower after a French cosmetic industry official reportedly said there is a retaliation risk from tariffs on US makeup.

Per RoundHill Investments <a href="https://blog.roundhillinvestments.com/roundhill-roundup-march-2025?utm_medium=email&amp;_hsenc=p2ANqtz--pHBY9m_LGLYfMguN84UP1iPLDr66n4D0jzpd4YV23i1CHUdHs6WJ_EnlPQ9oV1yzstXggaWE-3-fwCsXHwOIA71KPPQ&amp;_hsmi=350655792&amp;utm_content=350655792&amp;utm_source=hs_email " title="https://blog.roundhillinvestments.com/roundhill-roundup-march-2025?utm_medium=email&amp;_hsenc=p2ANqtz--pHBY9m_LGLYfMguN84UP1iPLDr66n4D0jzpd4YV23i1CHUdHs6WJ_EnlPQ9oV1yzstXggaWE-3-fwCsXHwOIA71KPPQ&amp;_hsmi=350655792&amp;utm_content=350655792&amp;utm_source=hs_email ">https://blog.roundhillinvestments.com/roundhill-roundup-march-2025?utm_medium=email&amp;_hsenc=p2ANqtz--pHBY9m_LGLYfMguN84UP1iPLDr66n4D0jzpd4YV23i1CHUdHs6WJ_EnlPQ9oV1yzstXggaWE-3-fwCsXHwOIA71KPPQ&amp;_hsmi=350655792&amp;utm_content=350655792&amp;utm_source=hs_email </a> &nbsp;

Equities

Broad U.S. Equity ETFs

ETFs

ACWI

SPDR Dow Jones Industrial Average ETF Trust

The Spread Between The American Association of Individual Investors (AAII) Bullish Minus Bearish Readings Has Reported Its 8th Most Bearish Reading In Its History Going Back To 1990. 19.4% Of Respondents Reported Bullish Expectations For The Direction Of The Stock Market Over The Next 6 Months, While 60.6% Reported Bearish Expectations.

Truist Securities analyst Greg Miller maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Hold and raises the price target from $163 to $175.

EXPE

Truist Securities Maintains Hold on Expedia Group, Raises Price Target to $175

Johnson Rice analyst Charles Meade upgrades Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) from Hold to Accumulate and announces $37 price target.

CTRA

Johnson Rice Upgrades Coterra Energy to Accumulate, Announces $37 Price Target

Raymond James analyst Ryan Deschner maintains Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Outperform and lowers the price target from $24 to $12.

INZY

Raymond James Maintains Outperform on Inozyme Pharma, Lowers Price Target to $12

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.skywatertechnology.com%2F&amp;esheet=54223252&amp;newsitemid=20250312867570&amp;lan=en-US&amp;anchor=SkyWater+Technology&amp;index=1&amp;md5=a44757027ccbf73759b45e5f3ff03bb6">SkyWater Technology</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>, or "SkyWater")), a U.S.-based Trusted technology realization partner, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dwavequantum.com%2F&amp;esheet=54223252&amp;newsitemid=20250312867570&amp;lan=en-US&amp;anchor=D-Wave+Quantum&amp;index=2&amp;md5=374a95b2258d9d6a9aad564e54b8e1e5">D-Wave Quantum</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>, or "D-Wave")), a leader in quantum computing systems, software and services, today announced that D-Wave's Advantage2&#x2122; annealing quantum computer prototype, fabricated by SkyWater, was used to achieve computational supremacy in quantum simulation. The landmark research was published today by the American Association for the Advancement of Science (AAAS), in its journal, Science, one of the world's most respected scientific journals, known for publishing high-impact research that advances global scientific and technological progress. The article details the work which demonstrates that D-Wave's superconducting annealing quantum computing processors can efficiently solve problems beyond the practical reach of classical computers. This breakthrough also underscores the vital role of U.S.-based manufacturing in advancing global technology leadership.
The peer-reviewed paper, "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.science.org%2Fdoi%2F10.1126%2Fscience.ado6285&amp;esheet=54223252&amp;newsitemid=20250312867570&amp;lan=en-US&amp;anchor=Beyond-Classical+Computation+in+Quantum+Simulation&amp;index=3&amp;md5=56d56907cf5acdb3391a36a51c4a7572">Beyond-Classical Computation in Quantum Simulation</a>," confirms that D-Wave's annealing quantum computer outperformed one of the world's most powerful classical supercomputers in solving complex magnetic materials simulation problems with relevance to materials discovery. Understanding the quantum nature of magnetic materials is crucial to finding new ways to use them for technological advancement, making materials simulation and discovery a vital area of research for D-Wave and the broader scientific community. Magnetic materials are widely used in medical imaging, electronics, superconductors, electrical networks, sensors and motors.
Through the ongoing partnership with D-Wave, which began a decade ago at the Minnesota fab, SkyWater has provided highly specialized process integration, materials engineering and thin film fabrication expertise, enabling D-Wave's concepts to be realized as manufacturable devices. SkyWater's advanced development capabilities, including custom material deposition, specialized device patterning and large-scale fabrication integration, together with D-Wave's superconducting materials and device expertise, have been integral in producing the qubits powering this major advancement.
Additionally, with SkyWater's DOD Trusted Foundry status and D-Wave's pioneering leadership in quantum computing, this partnership supports the rapidly growing commercialization of useful quantum computing solutions while reinforcing domestic leadership in advanced computing. U.S. semiconductor manufacturing strengthens national security, economic resilience and the country's leadership in the global race to develop advanced quantum capabilities. Furthermore, the milestone announced today highlights SkyWater's critical role in enabling innovators to conceive and scale next-generation advancements, underscoring the importance of expanding and safeguarding this crucial infrastructure to maintain U.S. leadership.

QBTS

SKYT

SkyWater Technology Reports D-Wave's Advantage2 Annealing Quantum Computer Prototype, Fabricated By SkyWater, Was Used To Achieve Computational Supremacy In Quantum Simulation; Research Was Published Today By The American Association For The Advancement Of Science

Raymond James analyst Joseph Altobello maintains Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Outperform and raises the price target from $3 to $3.5.

HLLY

Raymond James Maintains Outperform on Holley, Raises Price Target to $3.5

JP Morgan analyst Alex Yao upgrades Autohome (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATHM#NYSE">ATHM</a>) from Neutral to Overweight and raises the price target from $24 to $36.

ATHM

JP Morgan Upgrades Autohome to Overweight, Raises Price Target to $36

Health In Tech Shares Halted On Circuit Breaker To The Downside, Stock Now Down -80%

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

Comments

2seventy bio

매도 수량

2seventy bio (NASDAQ:TSVT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌